Communiqués Cipla Limited

Actions

CIPLA

INE059A01026

Produits pharmaceutiques

Marché Fermé - NSE India S.E. 13:05:07 30/09/2026			Varia. 5j.	Varia. 1 janv.
1 346,00 ^INR	-2,41%		-2,75%	-10,94%

22/09	Cipla Limited et Cipla Usa Inc. annoncent des changements au sein de leur direction, effectifs au 1er octobre 2026	CI
03/09	L'indien Cipla et le chinois Qilu s'associent pour le lancement aux États-Unis d'un biosimilaire du Keytruda de Merck	RE

Communiqués

04/09	Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the US	AQ
04/09	Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda(R) (Pembrolizumab) in the US	AQ
24/04	Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA	AQ
02/03	Cipla strengthens US portfolio with the launch of generic Saxenda(R) (Liraglutide Injection) for weight management therapy	AQ
02/03	Cipla strengthens US portfolio with the launch of generic Saxenda for weight management therapy	AQ
01/12	D. Mass. Patent Litigation Update: October 2025	AQ
29/10/25	Technical Advancement Required To Secure Patent: Delhi High Court Affirms	AQ
28/10/25	Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing	AQ
26/07/24	Cipla : Disclosure pursuant to SEBI (Share Based Employee Benefits and Sweat Equity Regulation), 2021	PU
26/07/24	Cipla : CSR Executive Summary - Impact Assessment Report	PU
26/07/24	Cipla : Details of capital assets created or acquired through CSR spent in FY 2023-24	PU
26/07/24	Cipla : CSR detailed Impact Assessment Report	PU
26/07/24	Cipla : Notice of 88th Annual General Meeting	PU
26/07/24	Cipla : Annual Report 2023-24 (Single page)	PU
26/07/24	Cipla : Annual Report 2023-24 (Double page)	PU
26/07/24	Cipla : Extract of Unaudited Consolidated Financial Results – 30 June, 2024	PU
26/07/24	Cipla : Annual Return 2023-24	PU
26/07/24	Cipla : Outcome of Board Meeting Q1 FY 25	PU
26/07/24	Cipla : Q1 FY25 Investor Presentation	PU
26/07/24	Cipla : Q1 FY25 Press Release	PU
26/07/24	Cipla : Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2024	PU
26/07/24	Cipla : Financial Statements of Subsidiaries FY 2023-24	PU
28/06/24	Cipla : Orchid Pharma partners with Cipla to launch antibiotic Cefepime - Enmetazobactam in India	PU
20/06/24	Cipla : signs a non-exclusive patent license agreement with Takeda to commercialize Vonoprazan drug in India	PU
19/06/24	Cipla EU to invest an additional EUR 3 million in Ethris	AQ